By Turna Ray

Clinical Data
is planning to submit a new drug application to the US Food and Drug Administration for its investigational depression drug vilazodone in the current quarter. However, due to unfavorable Phase III results on a response biomarker, the company will not be submitting its NDA with a pharmacogenomic companion test as previously hoped.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.